Goods shipped from the country face a 39% tariff in the U.S., which companies warn will have dire consequences if President ...

Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

Swiss leaders refrained from implementing countermeasures against sweeping US tariffs and instead want to focus on further ...

August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epco ...

Today, the regulator revealed FDA PreCheck, which introduces a two-phase approach to getting approval for new production ...

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

A new American Heart Association initiative is working to increase screening for lipoprotein(a) (Lp[a]) at community health ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Yet, within the past 24 hours, Trump has doubled the tariffs on India to 50%, imposed an additional 15% on Japan, announced a ...

The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, ...